Topics

GSK Submits sNDA to the FDA for Trelegy Ellipta for Use in Patients With Asthma

13:40 EDT 2 Oct 2019 | Speciality Pharma Journal

LONDON–(BUSINESS WIRE)–GlaxoSmithKline plc (GSK) and Innoviva, Inc. (INVA) today announced the filing of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) seeking an additional indication for the use of once-daily, single-inhaler triple therapy, Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol or FF/UMEC/VI), for the treatment of asthma in adults. Trelegy Ellipta was …

Original Article: GSK Submits sNDA to the FDA for Trelegy Ellipta for Use in Patients With Asthma

NEXT ARTICLE

More From BioPortfolio on "GSK Submits sNDA to the FDA for Trelegy Ellipta for Use in Patients With Asthma"

Quick Search

Relevant Topics

GlaxoSmithKline
GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...